Clinical Trial Oversight
Every deviation, one auditable record.
Running a pediatric study? Lock your patient materials first with Vera Simulate →
Clinical trial oversight for sponsors and CROs
ShownCRO-delegated setup. In-house or hybrid? Vera fits how you run your study.
Keep oversight of every deviation
You can delegate the work. You can't delegate the oversight.
- You enter nothing. You just decide.Cases arrive classified, reviewed and evidenced. Decide or request changes.
- Critical deviations don't wait for the meeting.Consent or sample issues go straight to a named decision-maker. Everything else goes to your data review meeting.
- Every decision is its own evidence.Each decision is recorded with a name, role and timestamp, then locked. Export to your eTMF at any time.
- Every source, one record.EDC, spreadsheets and paper site logs in one place. Vera reads, never writes back.
Show the oversight you were contracted to deliver
Your sponsor delegated the work. Vera proves you did it.
- Hand over finished cases, not spreadsheets.CRAs enter and classify. CPMs review before the sponsor sees it. Vera enforces independent operational review.
- Every step your team takes is on the record.Each step is logged with a name, role and timestamp. That's proof of delegated oversight for your sponsor and inspectors.
- Every source, reconciled as you go.Import EDC exports, spreadsheets or paper site logs. Repeats and missing SOP fields are flagged.
- Catch stalled deviations before the review meeting.See every open deviation's stage and age, and act in time.
- Imported and classifiedSource: site logCRA · 08 Jul 2026, 10:58 UTC
- Operational review: changes requestedAdd CAPAClinical PM · 22 Jul 2026, 09:42 UTC
- CAPA recordedRoot cause, correction, preventionCRA · 29 Jul 2026, 14:05 UTC
- Medical review: more information requestedMedical Monitor · 05 Aug 2026, 09:40 UTC
- Information providedCRA · 12 Aug 2026, 16:20 UTC
- Medical review: concurMedical Monitor · 19 Aug 2026, 10:11 UTC
- Approved for sponsor decisionClinical PM · 26 Aug 2026, 10:15 UTC
Why Vera: clinical trial oversight is about trust, not speed
Nothing changes in your sources
Vera reads exports from your EDC, Excel trackers and paper site logs, and never writes back. No migration, no integration project, no new system for your sites. Live in 3–6 weeks.
Independent review, built in
The person who creates a case can't operationally review it. Every step is recorded with name, role and time in an append-only audit trail.
Critical deviations don't wait for the meeting
Routine deviations go to your data review meeting. Consent or sample issues go straight to a named decision-maker, sent by your CRA as soon as the deviation is entered.
Could you show an inspector how you oversee deviations you've delegated?
10 inspector questions. See your gaps and what to ask your CRO.
Free · 5 minutes
How each question is tagged
- FDA regulationBinding law: informed consent and IRB rules (21 CFR 50 and 56)
- ICH E6(R3)Expected under the current GCP standard
- FDA guidanceRecommended in FDA’s draft guidance on protocol deviations
- Good practiceSupports a regulatory goal; how you meet it is up to you
Sources are listed at the end of the self-check.
0 of 10 answered
Your score
/ 10
Your study looks like the ones Vera was built for: deviations from several sources, assessments the EDC can't hold, and critical decisions that can't wait.
Your gaps, most weight first
This self-check is a conversation starter, not an audit or a regulatory assessment. Tags show where each question connects to FDA regulations, ICH E6(R3) or FDA’s December 2024 draft guidance on protocol deviations, which is nonbinding. Bionabu is not affiliated with or endorsed by FDA or ICH.
Sources · Last checked: 1 Oct 2026
ICH E6(R3) Good Clinical Practice: principles and Annex 1 in effect in the EU since 23 July 2025. Annex 2 (decentralised, pragmatic and real-world data trials) was adopted in June 2026 and takes effect on 15 January 2027.
FDA draft guidance Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices (December 2024, docket FDA-2023-D-5016). As of Oct 1, 2026, FDA lists it as current draft guidance, with no newer final or revised version. FDA regulations: 21 CFR 50 and 21 CFR 56.
Book a walkthrough
Tell us about your study
We’ll map your deviation oversight with you, from the first case to the final decision.
- A 30-minute walkthrough with Ina Burgstaller, founder of Vera Platform, with 20+ years in clinical trials.
- Built around your study: your categories, sources and roles.
We sign your NDA before you share anything.
Privacy questions: privacy@bionabu.com
Bring us your study
Free · 10 questions · 5 minutes
Pediatric study? Lock your patient materials first with Vera Simulate →
We sign your NDA before you share anything.